BC Innovations | Jan 23, 2019
Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest modulating SF3B1-mediated splicing alone or in combination with BCL-2 and Bcl-XL inhibitors could help treat MCL1-dependent NSCLC. In three human MCL1-dependent NSCLC cell...
BC Innovations | Nov 14, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer; prostate cancer Cell culture and mouse studies suggest Bcl-XL inhibitors could help treat glioma, prostate and other cancers harboring the IDH1 R123H mutation. In human glioma and prostate cancer cell lines, cells...
Items per page:
1 - 2 of 2